Newco Biscayne debuts with $1.5M and license to GHRH compounds

Newco Biscayne Pharmaceuticals Inc. (Miami, Fl.) debuted on Friday with $1.5 million in seed financing and an exclusive, worldwide license from the University of Miami to IP covering growth hormone-releasing hormone ( GHRH) compounds. The license covers GHRH receptor antagonists in preclinical development for castration-resistant prostate cancer (CRPC) and GHRH receptor agonists in preclinical development to repair damaged cardiac tissue. ...